Anticancer Therapy in COViD-19 Patients: A Descriptive Literature Review

To provide a descriptive literature review about the effects of anticancer treatment on clinical outcomes because of active COVID-19 infection in older people.

A literature search was conducted in Google Scholar, PubMed, American Society of Clinical Oncology, European Society for Medical Oncology, and the Center for Disease Control and Prevention. Articles published in English between December 1, 2019, to September 1, 2020, were included.

Nine studies assessing the effectiveness of various modalities for cancer treatments in patients infected with COVID-19 infection were reviewed. The studies reviewed the severity of COVID-19 infection outcomes in patients who underwent any anticancer treatment. Studies exclusively focused on older people could not be found, but all studies included older people. DATA SYNTHESiS AND RESULTS: Early pandemic studies suggested avoiding anticancer treatment during a COVID-19 infection because of poor clinical outcomes and increased mortality. However, the totality of studies reviewed found no association between the continuation of anticancer treatment and adverse COVID-19 outcomes in cancer patients. Adverse COVID-19 infection outcomes and high mortality rates were associated with older cancer patients independent of anticancer therapy.

Treatment of cancer could be challenging because of the COVID-19 pandemic. Interruption or delaying the anticancer therapy could increase the burden of overall mortality. This literature review indicated that adverse outcomes because of COVID-19 are associated with advanced age independent of anticancer therapy. Further exploration of the correlation between cancer, anticancer treatments, and COVID-19 infection outcomes is needed.